How Mycobacterium tuberculosis drug resistance has shaped anti-tubercular drug discovery
Authors:
Open Access
- 9 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 12, 974101
Abstract
Drug resistance is an increasing problem for the treatment of tuberculosis. The prevalence of clinical isolates with pre-existing resistance needs to be considered in any drug discovery program. Non-specific mechanisms of resistance such as increased efflux or decreased permeability need to be considered both in developing individual drug candidates and when designing novel regimens. We review a number of different approaches to develop new analogs and drug combinations or improve efficacy of existing drugs that may overcome or delay the appearance of clinical resistance. We also discuss the need to fully characterize mechanisms of resistance and cross- resistance to existing drugs to ensure that novel drugs will be clinically effective.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases
- Congressionally Directed Medical Research Programs
This publication has 86 references indexed in Scilit:
- Towards a new tuberculosis drug: pyridomycin – nature's isoniazidEMBO Molecular Medicine, 2012
- A new evolutionary and pharmacokinetic–pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugsCurrent Opinion in Pharmacology, 2011
- First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospitalClinical Microbiology and Infection, 2010
- Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosisProceedings of the National Academy of Sciences, 2009
- A Balancing Act: Efflux/Influx in Mycobacterial Drug ResistanceAntimicrobial Agents and Chemotherapy, 2009
- Meropenem-Clavulanate Is Effective Against Extensively Drug-Resistant Mycobacterium tuberculosisScience, 2009
- In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutationsClinical Microbiology and Infection, 2004
- The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosisNature, 1992
- The action of antituberculosis drugs in short-course chemotherapyTubercle, 1985
- The Chemotherapy of Pulmonary Tuberculosis: A ReviewChest, 1979